A study on the immunological vitality of an inflammatory biomarker explored with rs5743708 polymorphism in TLR2 gene among Saudi women confirmed with polycystic ovarian syndrome DOI Creative Commons
Amal F. Alshammary, Abdulrahman Alshammari, Raed Farzan

et al.

Saudi Journal of Biological Sciences, Journal Year: 2023, Volume and Issue: 30(7), P. 103687 - 103687

Published: May 19, 2023

Polycystic ovary syndrome (PCOS) is an ovarian health condition as well a long-term endocrine dysfunction that affects reproductive-aged women. Toll-like receptor 2 (TLR2) gene was linked to PCOS and chronic inflammation, the prevalence of obesity rising in Saudi Previous studies on rs5743708 polymorphism were documented In this study, we investigated molecular role TLR2 among women diagnosed with using Rotterdam criteria. Blood samples collected from 220 hospital-based case-control study; 110 remaining non-PCOS (control women). Biochemical analysis performed serum samples, EDTA blood. Genotyping for polymerase chain reaction-restriction fragment length analysis. both groups, clinical data calculated t-test, which revealed positive (p < 0.05) negative > associations. HWE supported 0.05). polymorphism, none genotypes, genetic models, or allele frequencies found be associated However, ANOVA regression analyses relationship weight BMI 0.0001). The not One predictions could 42.7% 73.6% obese, has been previous studies. This study suggests screening additional polymorphisms large sample size.

Language: Английский

Obesity and Dyslipidemia: A Review of Current Evidence DOI
Jelena Vekić, Aleksandra Stefanović, Aleksandra Zeljković

et al.

Current Obesity Reports, Journal Year: 2023, Volume and Issue: 12(3), P. 207 - 222

Published: July 6, 2023

Language: Английский

Citations

66
PPM1K-regulated impaired catabolism of branched-chain amino acids orchestrates polycystic ovary syndrome DOI Creative Commons
Liangshan Mu,

Zhenhong Ye,

Junhao Hu

et al.

EBioMedicine, Journal Year: 2023, Volume and Issue: 89, P. 104492 - 104492

Published: March 1, 2023

Language: Английский

Citations

29
Multimorbidität bei endokrinologischen Erkrankungen: Klinische Implikationen des PCOS DOI
Sita Arjune,

Cornelius Bollheimer,

Ruth Hanßen

et al.

DMW - Deutsche Medizinische Wochenschrift, Journal Year: 2025, Volume and Issue: 150(09), P. 496 - 502

Published: April 1, 2025

Polycystic ovary syndrome (PCOS) is one of the most common endocrinological disorders in women reproductive age. It affects up to 15% this population worldwide and characterized by a complex hormonal, metabolic dysfunction. In article, multimorbidity PCOS reviewed, with particular focus on clinical implications management disorder.

Language: Английский

Citations

1
The Anti-Mullerian Hormone as a Biomarker of Effectiveness of Metformin Hydrochloride Therapy in Polycystic Ovarian Syndrome and Insulin Resistance DOI Open Access
Nikoleta Parahuleva, Anna Mihaylova, Stanislava Harizanova

et al.

Healthcare, Journal Year: 2025, Volume and Issue: 13(8), P. 884 - 884

Published: April 11, 2025

Background/Objectives: Among the therapeutic options available for managing PCOS, metformin improves insulin sensitivity, reduces androgen levels, and helps restore menstrual regularity ovulation. While primarily used its metabolic effects, therapy may also influence reproductive parameters, including AMH which are pivotal in improving ovarian function predicting outcomes PCOS. The aim of this study was to search scientific literature analyze correlation between levels hydrochloride women with PCOS IR. Methods: A systematic review conducted using following keywords: polycystic syndrome, anti-Mullerian hormone, resistance, metformin, treatment, biomarker, syndrome. This aimed at investigating potential as a biomarker effectiveness patients Results: Metformin treatment has shown significant reductions serum prolonged therapy. As an sensitizer, hyperinsulinemia, suppresses hyperandrogenism. process inhibits growth antral follicles, is reflected decreased levels. Conclusions: Reductions improvements sensitivity can serve indicators efficacy enhancements these patients. could be considered prognostic marker evaluating decrease indicate improved reduction morphology. However, further research necessary confirm findings determine optimal dosages duration treatment.

Language: Английский

Citations

1
Probiotic therapy, a novel and efficient adjuvant approach to improve glycemic status: An umbrella meta-analysis DOI
Meysam Zarezadeh, Vali Musazadeh, Amir Hossein Faghfouri

et al.

Pharmacological Research, Journal Year: 2022, Volume and Issue: 183, P. 106397 - 106397

Published: Aug. 15, 2022

Language: Английский

Citations

29
Combined oral contraceptive pill compared with no medical treatment in the management of polycystic ovary syndrome: A systematic review DOI Creative Commons
Maria Forslund, Johanna Melin, Simon Alesi

et al.

Clinical Endocrinology, Journal Year: 2023, Volume and Issue: 99(1), P. 79 - 91

Published: March 20, 2023

Abstract Objective As part of the update International Evidence‐Based Guidelines for Assessment and Management polycystic ovary syndrome (PCOS), a systematic review was performed to inform evidence‐based recommendations. Design Systematic review. Only randomised controlled trial were included. Patients Women with PCOS; use combined oral contraceptive pills (COCP) compared no medical treatment. Measurements Outcomes designed in collaboration clinical experts, researchers, consumers. Critical outcomes included hirsutism, irregular cycles, quality life, body mass index (BMI), weight. Results 1660 publications identified, but only four studies No could be meta‐analysis. COCP treatment improved cycle regularity (100% vs. 0%, low certainty evidence). showed difference improvement hirsutism or BMI placebo lifestyle; lower weight after (mean [MD] −8.0 (95% confidence interval, CI −11.67); −4.33 kg); life (MD 1.2 [95% 0.96]; 1.44), these results all very evidence. Conclusion show that benefit regulation, other benefits potential adverse effects identified The is frontline PCOS, this still based on established efficacy broader general population. Our research PCOS seriously lacking should prioritised capture core reproductive, metabolic psychological important PCOS.

Language: Английский

Citations

19
Approach to Investigation of Hyperandrogenism in a Postmenopausal Woman DOI Creative Commons
Angelica Lindén Hirschberg

The Journal of Clinical Endocrinology & Metabolism, Journal Year: 2022, Volume and Issue: 108(5), P. 1243 - 1253

Published: Nov. 21, 2022

Abstract Postmenopausal hyperandrogenism is a condition caused by relative or absolute androgen excess originating from the ovaries and/or adrenal glands. Hirsutism, in other words, increased terminal hair growth androgen-dependent areas of body, considered most effective measure women. Other symptoms can be acne and androgenic alopecia development virilization, including clitoromegaly. may also associated with metabolic disorders such as abdominal obesity, insulin resistance, type 2 diabetes. Mild hyperandrogenic due to menopausal transition polycystic ovary syndrome, which likely common cause postmenopausal hyperandrogenism. Virilizing symptoms, on hand, ovarian hyperthecosis an androgen-producing tumor that could malignant. Determination serum testosterone, preferably tandem mass spectrometry, first step endocrine evaluation, providing important information degree excess. Testosterone &gt;5 nmol/L virilization requires prompt investigation rule out instance. To localize source excess, imaging techniques are used, transvaginal ultrasound magnetic resonance (MRI) for computed tomography MRI adrenals. Bilateral oophorectomy surgical removal main curative treatment will ultimately lead histopathological diagnosis. moderate treated antiandrogen therapy specific depending This review summarizes relevant causes women suggests principles clinical treatment.

Language: Английский

Citations

28
Caffeic acid's role in mitigating polycystic ovary syndrome by countering apoptosis and ER stress triggered by oxidative stress DOI Open Access

Yi‐Fen Chiang,

I‐Cheng Lin,

Ko‐Chieh Huang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2023, Volume and Issue: 166, P. 115327 - 115327

Published: Aug. 22, 2023

Polycystic ovary syndrome (PCOS) is a complex endocrine disorder that affects women of reproductive age, characterized by androgen-induced oxidative stress leading to several metabolic disorders. In this study, we investigated the potential therapeutic effect caffeic acid on PCOS and its underlying molecular mechanism. We used human ovarian granulosa cell line (KGN cells) induced hydrogen peroxide (H2O2) examine how influences protein expression stress-induced apoptosis-related markers. Our results indicate significantly inhibits intracellular reactive oxygen species (ROS) generation safeguards KGN cells against stress. For in vivo aspect our female Sprague-Dawley (SD) rats were utilized induce model using dehydroepiandrosterone (DHEA). Caffeic was then administered for duration 6 weeks. The outcomes revealed effectively improved irregular estrous cycles, fasting blood glucose levels, liver function, lipid profiles DHEA-induced rats. Additionally, it mitigated hyperandrogenism, enhanced steroidogenesis enzyme expression, modulated expression. findings strongly suggest holds promising reducing damage ameliorating PCOS-related complications modulating ER

Language: Английский

Citations

16
Effects of Glucagon-Like Peptide-1 Receptor Agonists on Gut Microbiota in Dehydroepiandrosterone-Induced Polycystic Ovary Syndrome Mice: Compared Evaluation of Liraglutide and Semaglutide Intervention DOI Creative Commons
Chuanhao Xiong,

Jingzhu Wu,

Yuhang Ma

et al.

Diabetes Metabolic Syndrome and Obesity, Journal Year: 2024, Volume and Issue: Volume 17, P. 865 - 880

Published: Feb. 1, 2024

Purpose: Polycystic ovary syndrome (PCOS) is a frequent cause of infertility in reproductive-age women. Our work aims to evaluate the effects glucagon-like peptide-1 receptor agonists (GLP-1RAs) on gut microbiota, with metabolic parameters including body weight and hormone profile PCOS. Patients Methods: Dehydroepiandrosterone (DHEA)-induced PCOS mice were established then treated two GLP-1RAs: liraglutide novel form semaglutide for four weeks. Changes measured. Fecal samples collected analyzed using metagenomic sequencing. Results: Liraglutide modulated both alpha beta diversity microbiota increased Bacillota-to-Bacteroidota ratio through up-regulating abundance butyrate-producing members Bacillota like Lachnospiraceae. Moreover, showed ability reverse altered microbial composition disrupted functions caused by Semaglutide Helicobacter (p < 0.01) which was only bacteria found negatively correlated weight. pathways involving porphyrin flavonoids after intervention. Conclusion: improved reproductive disorders modulating whole structure The greater efficacy loss compared observed intervention positively related . study may provide new ideas treatment underlying mechanisms GLP-1RAs improve Keywords: PCOS, GLP-1 agonists, metabolism

Language: Английский

Citations

6
Understanding hirsutism in PCOS DOI
Talita Fischer Oliveira, Fábio Vasconcellos Comim

Expert Review of Endocrinology & Metabolism, Journal Year: 2024, Volume and Issue: 19(2), P. 103 - 110

Published: Jan. 25, 2024

Introduction Hirsutism is a prevalent condition among women and represents primary clinical feature of polycystic ovary syndrome (PCOS).

Language: Английский

Citations

5